Insulin-like growth factor I expression in thyroid tumors

Eugenio Maiorano, Anna Ciampolillo, Giuseppe Viale, Patrick Maisonneuve, Antonio Ambrosi, Vincenzo Triggiani, Ersilia Marra, Elda Perlino

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Insulin-like growth factor 1 (IGF-1) likely is involved in thyrocyte proliferation via autocrine mechanisms, but limited data are available on its in vivo expression in thyroid neoplasms. This prompted us to explore IGF-1 expression at the protein and mRNA levels and IGF-1 receptor (IGF-1rec) immunore-activity in normal and neoplastic thyroids (50 adenomas and 53 carcinomas). We documented increased IGF-1 and IGF-1rec immunoreactivity in adenomas (31 of 50 and 40 of 50 cases, respectively) and carcinomas (38 of 53 and 42 of 53 cases) compared with normal thyroid, which only showed minimal immunoreactivity for the ligand and its receptor. A corresponding up- regulation of IGF-1 mRNA was documented in carcinomas, whereas adenomas exhibited down-regulated expression of IGF-1 mRNA. Immunoreactivity for IGF-1 and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patients' gender and age or with the stage of the tumors and the occurrence of lymph node metastases. These data emphasize a possible role of the IGF-1 system in thyroid tumorigenesis, as indicated by in vitro studies. In addition, the evaluation of IGF-1 and IGF- 1rec immunoreactivity might have clinical implications, because it positively correlates with the aggressiveness of these tumors.

Original languageEnglish
Pages (from-to)110-119
Number of pages10
JournalApplied Immunohistochemistry and Molecular Morphology
Volume8
Issue number2
DOIs
Publication statusPublished - Jun 2000

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Thyroid Gland
Neoplasms
Carcinoma
Thyroid Neoplasms
Adenoma
Messenger RNA
Somatomedin Receptors
IGF Type 1 Receptor
Carcinogenesis
Up-Regulation
Lymph Nodes
Neoplasm Metastasis
Ligands

Keywords

  • Growth factors
  • Insulin-like growth factor
  • Insulin-like growth factor receptor
  • Thyroid gland
  • Thyroid neoplasms

ASJC Scopus subject areas

  • Anatomy
  • Medical Laboratory Technology

Cite this

Insulin-like growth factor I expression in thyroid tumors. / Maiorano, Eugenio; Ciampolillo, Anna; Viale, Giuseppe; Maisonneuve, Patrick; Ambrosi, Antonio; Triggiani, Vincenzo; Marra, Ersilia; Perlino, Elda.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 8, No. 2, 06.2000, p. 110-119.

Research output: Contribution to journalArticle

Maiorano, Eugenio ; Ciampolillo, Anna ; Viale, Giuseppe ; Maisonneuve, Patrick ; Ambrosi, Antonio ; Triggiani, Vincenzo ; Marra, Ersilia ; Perlino, Elda. / Insulin-like growth factor I expression in thyroid tumors. In: Applied Immunohistochemistry and Molecular Morphology. 2000 ; Vol. 8, No. 2. pp. 110-119.
@article{ea20a3e3cda74a24b024461be62338f9,
title = "Insulin-like growth factor I expression in thyroid tumors",
abstract = "Insulin-like growth factor 1 (IGF-1) likely is involved in thyrocyte proliferation via autocrine mechanisms, but limited data are available on its in vivo expression in thyroid neoplasms. This prompted us to explore IGF-1 expression at the protein and mRNA levels and IGF-1 receptor (IGF-1rec) immunore-activity in normal and neoplastic thyroids (50 adenomas and 53 carcinomas). We documented increased IGF-1 and IGF-1rec immunoreactivity in adenomas (31 of 50 and 40 of 50 cases, respectively) and carcinomas (38 of 53 and 42 of 53 cases) compared with normal thyroid, which only showed minimal immunoreactivity for the ligand and its receptor. A corresponding up- regulation of IGF-1 mRNA was documented in carcinomas, whereas adenomas exhibited down-regulated expression of IGF-1 mRNA. Immunoreactivity for IGF-1 and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patients' gender and age or with the stage of the tumors and the occurrence of lymph node metastases. These data emphasize a possible role of the IGF-1 system in thyroid tumorigenesis, as indicated by in vitro studies. In addition, the evaluation of IGF-1 and IGF- 1rec immunoreactivity might have clinical implications, because it positively correlates with the aggressiveness of these tumors.",
keywords = "Growth factors, Insulin-like growth factor, Insulin-like growth factor receptor, Thyroid gland, Thyroid neoplasms",
author = "Eugenio Maiorano and Anna Ciampolillo and Giuseppe Viale and Patrick Maisonneuve and Antonio Ambrosi and Vincenzo Triggiani and Ersilia Marra and Elda Perlino",
year = "2000",
month = "6",
doi = "10.1097/00022744-200006000-00005",
language = "English",
volume = "8",
pages = "110--119",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Insulin-like growth factor I expression in thyroid tumors

AU - Maiorano, Eugenio

AU - Ciampolillo, Anna

AU - Viale, Giuseppe

AU - Maisonneuve, Patrick

AU - Ambrosi, Antonio

AU - Triggiani, Vincenzo

AU - Marra, Ersilia

AU - Perlino, Elda

PY - 2000/6

Y1 - 2000/6

N2 - Insulin-like growth factor 1 (IGF-1) likely is involved in thyrocyte proliferation via autocrine mechanisms, but limited data are available on its in vivo expression in thyroid neoplasms. This prompted us to explore IGF-1 expression at the protein and mRNA levels and IGF-1 receptor (IGF-1rec) immunore-activity in normal and neoplastic thyroids (50 adenomas and 53 carcinomas). We documented increased IGF-1 and IGF-1rec immunoreactivity in adenomas (31 of 50 and 40 of 50 cases, respectively) and carcinomas (38 of 53 and 42 of 53 cases) compared with normal thyroid, which only showed minimal immunoreactivity for the ligand and its receptor. A corresponding up- regulation of IGF-1 mRNA was documented in carcinomas, whereas adenomas exhibited down-regulated expression of IGF-1 mRNA. Immunoreactivity for IGF-1 and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patients' gender and age or with the stage of the tumors and the occurrence of lymph node metastases. These data emphasize a possible role of the IGF-1 system in thyroid tumorigenesis, as indicated by in vitro studies. In addition, the evaluation of IGF-1 and IGF- 1rec immunoreactivity might have clinical implications, because it positively correlates with the aggressiveness of these tumors.

AB - Insulin-like growth factor 1 (IGF-1) likely is involved in thyrocyte proliferation via autocrine mechanisms, but limited data are available on its in vivo expression in thyroid neoplasms. This prompted us to explore IGF-1 expression at the protein and mRNA levels and IGF-1 receptor (IGF-1rec) immunore-activity in normal and neoplastic thyroids (50 adenomas and 53 carcinomas). We documented increased IGF-1 and IGF-1rec immunoreactivity in adenomas (31 of 50 and 40 of 50 cases, respectively) and carcinomas (38 of 53 and 42 of 53 cases) compared with normal thyroid, which only showed minimal immunoreactivity for the ligand and its receptor. A corresponding up- regulation of IGF-1 mRNA was documented in carcinomas, whereas adenomas exhibited down-regulated expression of IGF-1 mRNA. Immunoreactivity for IGF-1 and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patients' gender and age or with the stage of the tumors and the occurrence of lymph node metastases. These data emphasize a possible role of the IGF-1 system in thyroid tumorigenesis, as indicated by in vitro studies. In addition, the evaluation of IGF-1 and IGF- 1rec immunoreactivity might have clinical implications, because it positively correlates with the aggressiveness of these tumors.

KW - Growth factors

KW - Insulin-like growth factor

KW - Insulin-like growth factor receptor

KW - Thyroid gland

KW - Thyroid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0033865463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033865463&partnerID=8YFLogxK

U2 - 10.1097/00022744-200006000-00005

DO - 10.1097/00022744-200006000-00005

M3 - Article

VL - 8

SP - 110

EP - 119

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 2

ER -